Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olaparib

FDA-approved product (capsule, oral), marketed as Lynparza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Olaparib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Poly (adp-ribose) polymerase (parp) inhibitors
FDA pharmacologic class
Poly(ADP-Ribose) Polymerase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olaparib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olaparib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC

    NCT01562210 · start 2012-04

    Registered record
    Registry ID
    NCT01562210
    Conditions
    NSCLC
    Interventions
    Olaparib; Cisplatin; Radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2020-03-13
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionOlaparib; Cisplatin; Radiation
    PhasePhase 1
    Registry statusCompleted

  • Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

    NCT01296763 · start 2011-01

    Registered record
    Registry ID
    NCT01296763
    Conditions
    Pancreatic Cancer
    Interventions
    Irinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2); Mitomycin-C
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01
    Completion
    2016-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionIrinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2) +1 more
    PhasePhase 1
    Registry statusCompleted

  • AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

    NCT01445418 · start 2008-05-12

    Registered record
    Registry ID
    NCT01445418
    Conditions
    Breast Cancer; Ovarian Cancer
    Interventions
    AZ2281 + Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-05-12
    Completion
    2019-10-18
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Ovarian Cancer
    InterventionAZ2281 + Carboplatin
    PhasePhase 1
    Registry statusCompleted

  • AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

    NCT00535353 · start 2008-01-02

    Registered record
    Registry ID
    NCT00535353
    Conditions
    Colorectal Cancer
    Interventions
    irinotecan hydrochloride; olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01-02
    Completion
    2015-02-13
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionirinotecan hydrochloride; olaparib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

    NCT00516373 · start 2005-07-11

    Registered record
    Registry ID
    NCT00516373
    Conditions
    Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein
    Interventions
    KU-0059436 (AZD2281)(PARP inhibitor)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07-11
    Completion
    2023-04-26
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms; BRCA1 Protein; BRCA2 Protein
    InterventionKU-0059436 (AZD2281)(PARP inhibitor)
    PhasePhase 1
    Registry statusCompleted